Skip to content

Evaluation of Electrostimulation Program During Dialysis Sessions in Chronic Renal Failure Patients

Evaluation of Electrostimulation Program During Dialysis Sessions in Chronic Renal Failure Patients

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT01282554
Acronym
EMS-Dialyse
Enrollment
68
Registered
2011-01-25
Start date
2011-01-31
Completion date
2013-05-31
Last updated
2023-05-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Chronic Renal Failure (CRF)

Brief summary

Sport improves quality of life and health, decreasing cardiovascular risks and increasing effort tolerance. Chronic renal failure (CRF) induces many clinical and biological complications leading to less effort tolerance (strength and endurance). Renal failure patients got also many cardiovascular risks : sedentarily lifestyle, hypertension (HTA), diabetes, neuropathies, bone disorders, depression and sedentarity due to dialysis sessions. Moreover, dialysis sessions three times a week induce the spiral of deconditioning. In order to counteract this, sport should be encourage in this specific hemodialysis population. The aim of this study is to evaluate electrostimulation program during dialysis sessions for 3 months. Evaluation will be done using the Test of 6-minute walk (6MWT). Secondary aims will be evaluated: * Muscular strength and quadriceps diameter * Equilibrium * Quality of life. * Strength developed during maximal exercise test in a subgroup (patient undergoing dialysis in Rennes center, about 40% of the total population) * Nutritional intakes (quantitative and qualitative evaluation)

Detailed description

The primary outcome is the difference between distances during the 6 minutes walk test before and after the 3 month program between the stimulated and the non stimulated group. The secondary outcomes will be evaluated by maximum strength developed during the ergometry, limited by symptoms; maximal charge during muscular test; quadricipital diameter; time for the Timed up and go test; quality of life scores. All those scores will be evaluated in the control and stimulated groups before and after the 3 month period. This is an open randomized controlled study. Tests will be done by an investigator unaware of the stimulation group. The study is designed to detect a difference of 61 m (+/- 80 m) (6MWT) before and after stimulation in the stimulated group and 0 in the control group. This difference has been based on a pilot study with ergocycle in the same population and on literature in other populations (chronic respiratory failure or post cardiac surgery). We estimated that 70 patients would need to be enrolled in each group to provide 90% statistical power with a bilateral test.

Interventions

DEVICEelectrostimulation program (Rehab 400)

electrostimulation program (Rehab 400) : electrostimulation program during dialysis sessions for 3 months. Electrostimulation modalities have been chosen to seek both slow and fast muscle fibers : 35 Hz ; impulsion time: 400 µsec ; on/ off : 7'' contraction / 8'' relaxation. Stimulated muscles are quadriceps. Electrostimulation time will be 30 minutes. Each patient will individually regulate work intensity, maximal intensity should be the maximal tolerable intensity. Electrostimulation will be done 3 times per week. In case of asthenia or medical condition, electrostimulation can be delayed. The program will take place for 3 months.

Sponsors

Rennes University Hospital
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* Patients, \> 18 y/o, undergoing chronic hemodialysis since more than 3 months. * Physical activity score (Voorrips test) \<9.4 * Patients clinically and hemodynamically stable. * No major drug or dialysis treatment changes since 2 weeks * Written consent signed.

Exclusion criteria

* Relative or absolute contraindication to ergotest (ACC/AHA, 2002) and/or physical reentrainment. * Incapacity to practice the Test of 6-minute walk (6MWT) or ergotest * Clinical instability during hemodialysis sessions. * Hb\<9g/dl despite medical treatment ; PAS ≥180 mmHg et/ou PAD ≥110 mmHg despite medical treatment ; * Cardiac pace maker or defibrillator ; * Pregnancy ; * Recent cardiovascular events: cardiac failure less than 10 days before, instable angina, coronary angioplasty less than 10 days cardiac surgery less than 1 month, valvulopathy requiring surgery, myopericarditis, severe Rhythm troubles despite medical treatment, stade IV arteriopathy. * BMI ≥ 30 kg/m² ; * Anxiety and mental disorder * Concomitant pathology leading to severe general status alteration. * Patient participating to another medical study * Electromyostimulation or effort entrainment program less than a month. * Patients on renal transplantation awaiting list. * Patient practicing sport ( response to Voorips test)

Design outcomes

Primary

MeasureTime frameDescription
difference between distances during the 6 minutes walk test before and after the 3 month program between the stimulated and the non stimulated group3 monthsThe primary outcome is the difference between distances during the 6 minutes walk test before and after the 3 month program between the stimulated and the non stimulated group

Secondary

MeasureTime frameDescription
maximum strength developed during the ergometry, limited by symptoms; maximal charge during muscular test; quadricipital diameter; time for the Timed up and go test; quality of life scores.3 monthsThe secondary outcomes will be evaluated by maximum strength developed during the ergometry, limited by symptoms; maximal charge during muscular test; quadricipital diameter; time for the Timed up and go test; quality of life scores. All those scores will be evaluated in the control and stimulated groups before and after the 3 month period.

Countries

France

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026